Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)

Trial Profile

Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Aspirin (Primary) ; Clopidogrel (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms SMART-DATE
  • Most Recent Events

    • 01 Mar 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 01 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Dec 2016 Trial design published in the American Heart Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top